Impact of disease-modifying therapy on dendritic cells and exploring their immunotherapeutic potential in multiple sclerosis

Journal of Neuroinflammation

Review

Yan Mi¹  Caiyun Liu¹  Tao Jin¹  Jie Zhu² 

[1] Neuroscience Center, Department of Neurology, The First Hospital of Jilin University, Changchun, China;Neuroscience Center, Department of Neurology, The First Hospital of Jilin University, Changchun, China;Department of Neurobiology, Care Sciences & Society, Division of Neurogeriatrcs, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden;

关键词: Multiple sclerosis;    Immunotherapy;    Tolerance;    Dendritic cell;   

DOI  :  10.1186/s12974-022-02663-z

 received in 2022-06-28, accepted in 2022-12-01,  发布年份 2022

来源: Springer

【 摘 要 】

Dendritic cells (DCs) are the most potent professional antigen-presenting cells (APCs), which play a pivotal role in inducing either inflammatory or tolerogenic response based on their subtypes and environmental signals. Emerging evidence indicates that DCs are critical for initiation and progression of autoimmune diseases, including multiple sclerosis (MS). Current disease-modifying therapies (DMT) for MS can significantly affect DCs’ functions. However, the study on the impact of DMT on DCs is rare, unlike T and B lymphocytes that are the most commonly discussed targets of these therapies. Induction of tolerogenic DCs (tolDCs) with powerful therapeutic potential has been well-established to combat autoimmune responses in laboratory models and early clinical trials. In contrast to in vitro tolDC induction, in vivo elicitation by specifically targeting multiple cell-surface receptors has shown greater promise with more advantages. Here, we summarize the role of DCs in governing immune tolerance and in the process of initiating and perpetuating MS as well as the effects of current DMT drugs on DCs. We then highlight the most promising cell-surface receptors expressed on DCs currently being explored as the viable pharmacological targets through antigen delivery to generate tolDCs in vivo.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

Fig. 2